Finance

Lists
NONOF:OTCMKTS
Novo Nordisk A/S
42,62 US$
+1,48%
(+0,62) 1D
18 სექ, 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NONOF...
Open
42,34 US$
High
43,33 US$
Low
42,06 US$
Mkt. cap
145,43 მლრ.
Avg. vol.
120,14 ათ.
Volume
747,26 ათ.
52-wk high
64,75 US$
52-wk low
34,00 US$
Beta
0,63
Shares outstanding
3,39 მლრდ.
No. of employees
67 ათ.
Open
42,34 US$
High
43,33 US$
Low
42,06 US$
Mkt. cap
145,43 მლრ.
Avg. vol.
120,14 ათ.
Volume
747,26 ათ.
52-wk high
64,75 US$
52-wk low
34,00 US$
Beta
0,63
Shares outstanding
3,39 მლრდ.
No. of employees
67 ათ.
News stories
From web sources and news partners
Profile
Novo is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo is controlled by majority shareholder Novo Holdings A/S which holds approximately 28.1% of its shares and a majority of its voting shares. Novo manufactures and markets pharmaceutical products and services, primarily diabetes and obesity medications and devices. Novo employs more than 48,000 people globally, and markets its products in 168 countries. The corporation was created in 1989, through a merger of two Danish companies, which date back to the 1920s. Novo is a full member of the European Federation of Pharmaceutical Industries and Associations. The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights, while spin-off company Novozymes was named fourth. It is a leader in the FTSE4Good Index, and the only European company in the top ten. Novo is the largest pharmaceutical company in Denmark. Wikipedia
About Novo Nordisk A/S
CEOმაზიარ მაიკ დუსტარ
Employees66,7 ათ.
Founded21 დეკ. 1923
HeadquartersBagsværd, დედაქალაქის რეგიონი, დანია
SectorPharmaceutical industry
Websitenovonordisk.com
Previous reportsAll values in DKK
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in DKK
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
74,98 მლრდ.
79,14 მლრდ.
96,82 მლრდ.
78,49 მლრდ.
Cost of goods sold
14,47 მლრდ.
14,17 მლრდ.
13,60 მლრდ.
17,10 მლრდ.
Cost of revenue
14,47 მლრდ.
14,17 მლრდ.
13,60 მლრდ.
17,10 მლრდ.
Research and development expenses
11,49 მლრდ.
12,67 მლრდ.
10,28 მლრდ.
11,46 მლრდ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
15,76 მლრდ.
17,14 მლრდ.
13,22 მლრდ.
16,31 მლრდ.
Operating expense
27,25 მლრდ.
29,73 მლრდ.
23,61 მლრდ.
28,00 მლრდ.
Total operating expenses
41,72 მლრდ.
43,90 მლრდ.
37,20 მლრდ.
45,10 მლრდ.
Operating income
33,25 მლრდ.
35,24 მლრდ.
59,62 მლრდ.
33,39 მლრდ.
Other non operating income
1,53 მლრდ.
-241,00 მლნ.
-
-
EBT including unusual items
25,52 მლრდ.
34,18 მლრდ.
62,17 მლრდ.
26,88 მლრდ.
EBT excluding unusual items
35,09 მლრდ.
37,62 მლრდ.
62,17 მლრდ.
33,20 მლრდ.
Income tax expense
5,51 მლრდ.
7,29 მლრდ.
13,62 მლრდ.
5,89 მლრდ.
Effective tax rate
21,60%
21,34%
21,90%
21,90%
Other operating expenses
-
-81,00 მლნ.
106,00 მლნ.
234,00 მლნ.
Net income
20,01 მლრდ.
26,89 მლრდ.
48,56 მლრდ.
20,99 მლრდ.
Net profit margin
26,68%
33,98%
50,15%
26,74%
Earnings per share
4,50
6,04
6,63
6,18
Interest and investment income
307,00 მლნ.
4,41 მლრდ.
-
1,31 მლრდ.
Interest expense
-
-4,97 მლრდ.
-
-1,50 მლრდ.
Net interest expenses
307,00 მლნ.
-560,00 მლნ.
-
-186,00 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
36,49 მლრდ.
36,66 მლრდ.
63,13 მლრდ.
36,99 მლრდ.
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები